<DOC>
	<DOCNO>NCT01477606</DOCNO>
	<brief_summary>This phase II , single-arm , open-label , multi-center study adult patient Acute Myeloid Leukemia ( AML ) FLT3-ITD define inclusion/exclusion criterion . The primary efficacy object evaluate impact midostaurin give combination intensive induction , consolidation include allogeneic hematopoietic stem cell transplantation single agent maintenance therapy event-free survival ( EFS ) adult patient AML exhibit FLT3-ITD . Sample size : 440 patient The treatment duration individual patient 18 24 month . Duration study individual patient include treatment ( induction , consolidation [ chemotherapy allogeneic SCT ] , maintenance follow-up period : Maximum 7.5 year</brief_summary>
	<brief_title>Protocol Acute Myeloid Leukemia With FLT3-ITD</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Patients suspect diagnosis AML relate precursor neoplasm , acute leukemia ambiguous lineage ( classify accord World Health Organization ( WHO ) 2008 classification ) Presence FLT3ITD assess central AMLSG reference laboratory Patients consider eligible intensive chemotherapy WHO performance status ≤ 2 Age ≥ 18 year ≤ 70 year No prior chemotherapy leukemia except hydroxyurea control hyperleukocytosis ( ≤ 7 day ) Nonpregnant nonnursing . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within sensitivity least 25 mIU/mL within 72 hour prior registration ( `` Women childbearing potential '' define sexually active mature woman undergone hysterectomy menses time precede 24 consecutive month ) Female patient reproductive age male patient must agree avoid get pregnant father child therapy 5 month last dose chemotherapy Women childbearing potential must either commit continued abstinence heterosexual intercourse begin one acceptable method birth control ( IUD , tubal ligation , partner 's vasectomy ) . Hormonal contraception inadequate method birth control Men must use latex condom sexual contact woman childbearing potential , even undergone successful vasectomy ( therapy 5 month last dose chemotherapy ) Signed write informed consent . •AML follow recurrent genetic abnormality ( accord WHO 2008 ) : AML ( 8 ; 21 ) ( q22 ; q22 ) ; RUNX1RUNX1T1 AML inv ( 16 ) ( p13.1q22 ) ( 16 ; 16 ) ( p13.1 ; q22 ) ; CBFBMYH11 AML ( 15 ; 17 ) ( q22 ; q12 ) ; PMLRARA ( variant translocation RARA gene fusion ) Performance status WHO &gt; 2 Patients ejection fraction &lt; 50 % MUGA ECHO scan within 14 day day 1 Organ insufficiency ( creatinine &gt; 1.5x upper normal serum level ; bilirubin , AST ALP &gt; 2.5x upper normal serum level , attributable AML ; heart failure NYHA III/IV ; severe obstructive restrictive ventilation disorder ) Uncontrolled infection Severe neurological psychiatric disorder interfere ability give informed consent Patients `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse within one year Known positive HIV ; active HBV , HCV , Hepatitis A infection Bleeding disorder independent leukemia No consent registration , storage process individual diseasecharacteristics course well information family physician and/or physician involve treatment patient study participation . No consent biobanking .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>FLT3-ITD</keyword>
	<keyword>midostaurin ( PKC412 )</keyword>
</DOC>